Activation of the aryl hydrocarbon receptor by doxorubicin mediates cytoprotective effects in the heart
Open Access
- 13 January 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 90 (2), 305-314
- https://doi.org/10.1093/cvr/cvr007
Abstract
Doxorubicin (DOX) is a highly effective chemotherapeutic agent; however, cumulative dose-dependent cardiotoxicity is a significant side effect of this therapy. Because DOX is a polyaromatic hydrocarbon, we hypothesized that it will be metabolized by the activation of the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor that is involved in the metabolism of numerous xenobiotic agents. These studies were performed to determine whether DOX activates AhR and whether this activation modulates the toxicity of DOX in cardiomyocytes. Treatment with DOX induced AhR migration to the nucleus, increased AhR binding with its co-factor, aryl hydrocarbon receptor nuclear translocator-1 (ARNT1), and increased the expression of AhR-regulated phase I (CYP1A1) and phase II (GSTA1) drug-metabolizing enzymes in both cardiomyocytes and in the intact heart. Knockdown of AhR in H9C2 cells abolished DOX-induced increases in CYP1A1 and GSTA1 expression. Similar results were obtained by treating adult rat ventricular myocytes with the AhR antagonist, CH-223191. Taken together, these findings indicate that DOX-induced upregulation of CYP1A1 and GSTA1 expression is AhR dependent. AhR null mice treated with 10 mg/kg DOX did not show any activation of CYP1A1 or GSTA1 expression. Moreover, lack of AhR in vivo resulted in a significant decrease in left ventricular function compared with wild-type animals, and increased p53 activation and apoptosis in the heart after treatment with DOX. These findings indicate that AhR plays an important role in DOX metabolism by the heart and further demonstrate that AhR is cardioprotective against DOX-induced cardiotoxicity.Keywords
This publication has 57 references indexed in Scilit:
- CH223191 Is a Ligand-Selective Antagonist of the Ah (Dioxin) ReceptorToxicological Sciences, 2010
- Transcription Factor GATA4 Inhibits Doxorubicin-induced Autophagy and Cardiomyocyte DeathOnline Journal of Public Health Informatics, 2010
- Dioxin Receptor Deficiency Impairs Angiogenesis by a Mechanism Involving VEGF-A Depletion in the Endothelium and Transforming Growth Factor-β Overexpression in the StromaOnline Journal of Public Health Informatics, 2009
- Expression of CYP1A1 and CYP1B1 in human endothelial cells: regulation by fluid shear stressCardiovascular Research, 2009
- ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytesAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Aryl Hydrocarbon Receptor Is Activated by Glucose and Regulates the Thrombospondin-1 Gene Promoter in Endothelial CellsCirculation Research, 2008
- Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancerBreast Cancer Research and Treatment, 2006
- Multiple actions of pifithrin-α on doxorubicin-induced apoptosis in rat myoblastic H9c2 cellsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999
- Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on guinea pig heart muscleToxicology and Applied Pharmacology, 1987